Episode 242: ASCO 2023 - The THOR Study: Erdafitinib vs Chemotherapy in Bladder Cancer

By The Uromigos - Last Updated: July 17, 2023

Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the survival benefit of erdafitinib for advanced urothelial carcinoma while at the American Society of Clinical Oncology 2023 Annual Meeting.
Dr. Loriot is a physician scientist and director of the Universit√© Paris-Saclay’s bladder cancer program.

Post Tags:Uromigos-ASCOUromigos-ASCO 2023-Bladder CancerUromigos-Bladder Cancer